Insider
Resmed IncRMD

ResMed grew revenue 8% and returned over $1 billion to shareholders in 2026

ResMed reported that for fiscal year 2026 revenue grew 8% in constant currency, free cash flow exceeded $1.6 billion, and the company returned more than $1 billion to shareholders. It completed the acquisition of Noctrix Health for $340 million, and proceeds from the MatrixCare sale are being used for an accelerated share repurchase (ASR).

Verified against 1 archived primary source · SHA-256 recorded Inspect sources & citations ↓
hospital bed near couch
Photo by Martha Dominguez de Gouveia on Unsplash
$1.6 billion
Free cash flow
$1 billion
Shareholder return
$340 million
Acquisition price

What happened

ResMed said revenue in constant currency jumped 8%, earnings per share (EPS) rose 17%, and free cash flow topped $1.6 billion. The company also returned over $1 billion to shareholders via dividends and share repurchases, 70% more than the prior year.

The $340 million acquisition of Noctrix Health was completed, and on September 1, 2026 the MatrixCare business was sold, with the proceeds earmarked for an accelerated share repurchase (ASR).

Key financial metrics 2026

Revenue growth
8%
EPS growth
17%
Free cash flow
$1.6 billion
Data from the original sources listed alongside.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

What to watch

Watch the constant‑currency revenue growth rate in the 2027 fiscal report.

Check whether 2027 free cash flow remains above $1.6 billion.

Assess 2027 shareholder returns to gauge continuation of dividends and repurchases.

Integration of Noctrix Health and its sales contribution will be detailed in a future report.

Original sources

  1. DEF 14A filing, October 1, 2026October 1, 2026SHA-256 of our archived copy faf3d8331d9b…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards